NASDAQ · Biotechnology · USD
Minerva Neurosciences, Inc. (NERV) Stock Analysis
Minerva Neurosciences, Inc. (NERV) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
NERV Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.53
- Previous Close
- $2.53
- Day's Range
- 2.39–2.53
- 52-Week Range
- 2.24–8.80
- Volume
- 101.54K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- −0.12
Valuation
- Market Cap
- $114.12M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −36.12
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$293.42M−20,492.68%
- Shares Outstanding
- 47.75M
- 1-Year Return
- −62.71%
Dividend and dates
- Avg Volume
- 180.09K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, NERV closed at $2.39, −62.71% over 1 year.
Minerva Neurosciences, Inc. (NERV) has a market capitalization of $114.12M.
In fiscal 2025, NERV reported revenue of $0.00.
NERV Stock Return by Calendar Year
Minerva Neurosciences, Inc. (NERV) 10-year return: what $10,000 became
- 1 year
- $10,000 $3,729
- −62.71%
- 5 years
- $10,000 $2,298
- −77.02%
- 10 years
- $10,000 $232
- −97.68%
If you had invested $10,000 in Minerva Neurosciences, Inc. (NERV) 10 years ago, at the close on October 21, 2016, it would have been worth $232 at the close on October 21, 2026: −97.68% in total, −31.35% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −40.55% |
| 2025 | +80.92% |
| 2024 | −63.87% |
| 2023 | +286.79% |
| 2022 | −75.19% |
| 2021 | −65.77% |
| 2020 | −67.09% |
| 2019 | +5.49% |
| 2018 | +11.40% |
| 2017 | −48.51% |
| 2016 (partial year) | +1.29% |
As of October 21, 2026.
NERV Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$293.42M | — |
| 2024 | $0.00 | $1.44M | — |
| 2023 | $0.00 | −$30.01M | — |
| 2022 | $0.00 | −$32.11M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$15.10M | −$293.42M | — |
| 2024 | $0.00 | — | −$21.85M | $1.44M | — |
| 2023 | $0.00 | — | −$23.12M | −$30.01M | — |
| 2022 | $0.00 | — | −$25.23M | −$32.11M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Jefferies Upgrades Minerva Neurosciences to Buy, Raises Price Target to $10
BenzingaMinerva Neurosciences Q2 Adj. EPS $(0.10) Beats $(0.12) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B